Case Report

Endolymphatic exclusion for the treatment of pediatric chylous ascites secondary to neuroblastoma resection: report of two cases ★★✩✩✩,ﬄ,f

Andrew Woerner, MD, MSa, David S. Shin, MDa, Jeffrey Forris Beecham Chick, MD, MPH, FSVMa,b, Caitlin A. Smith, MDb, Jay F. Sarthy, MD, PhDa,b,c, Eric J. Monroe, MDb,b,*

a Interventional Radiology Section, Department of Radiology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA
b Division of Vascular and Interventional Radiology, Department of Radiology, Seattle Children’s Hospital, 4800 Sand Point Way Northeast, Seattle, WA 98105, USA
c Department of General Surgery, University of Washington and Seattle Children’s Hospital, Seattle, WA, USA
d Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
e Cancer and Blood Disorders Center, Seattle Children’s Hospital, Seattle, WA, USA

A R T I C L E   I N F O

Article history:
Received 21 April 2020
Revised 27 April 2020
Accepted 27 April 2020

Keywords:
Pediatrics
Oncology
Chylous ascites
Lymphatic
Interventional radiology
Cone beam computed tomography

A B S T R A C T

Chylous ascites is a rare, but highly morbid complication of oncologic resection, often associated with retroperitoneal lymphadenectomy. Conservative measures with total parenteral nutrition or lipid-reduced formulas constitute the initial mainstay therapy, but not without risks and failures. This report describes 2 endolymphatic treatment strategies for iatrogenic chylous ascites following neuroblastoma resection. Lymphatic leaks were identified using intranodal lymphangiography, targeted with cone-beam computed tomographic guidance, and embolized with n-butyl cyanoacrylate. There were no adverse outcomes, with complete resolution of chylous ascites and a mean follow-up of 26 months.

© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
dissection. Incidence of chyous ascites in this setting ranges from 2% to 11% [1–3].

Despite its overall low incidence, chyous ascites results in significant morbidity. The loss of chyle, which is rich in proteins, lipids, immunoglobulins, electrolytes, and vitamins, depletes many elements that are vital to normal physiology [4]. Nutritional and electrolyte deficiencies require total parenteral nutrition and fluid replenishment. Loss of lymphocytes and immunoglobulins contributes to immunosuppression [5]. There are also reports of diminished bioavailability of certain drugs with chyle losses [6–8]. These complications may extend hospital stays, increase postoperative mortality, and delay or preclude adjuvant chemotherapy [9].

Conservative treatment measures, including enteral feeding, total parenteral nutrition, and somatostatin analogs, constitute the initial medical management. Reported success rates of these conservative methods range from 60% to 100% over 2–6 weeks of treatment [9,10]. Major drawbacks to these approaches include complications of long-term central venous access, malnutrition, neurological developmental deficits from fatty acid deficient diet, and extended hospitalizations [9,11–13].

Various endolymphatic interventions offer a less invasive approach for definitive management of refractory chyous ascites [14–16]. These described interventions have, however, been largely reported in adults. This report describes 2 pediatric patients with persistent iatrogenic chyous ascites that were successfully managed with endolymphatic embolization.

**Case report**

**Patient 1**

A 5-year-old male patient presented with 1 month of periorbital ecchymosis. Diagnostic evaluation revealed a 7.6 × 7.1 × 9.5 cm right adrenal mass, pancytopenia, splenoid and occipital bone lesions, and bone marrow infiltration consistent with high-risk neuroblastoma. After his fourth cycle of chemotherapy per ANBL0532, he underwent right adrenalectomy, retroperitoneal lymphadenectomy, and non-segmental liver resection. Large volume chyous ascites developed 2 weeks after surgery upon resolution of ileus and initiation of total parenteral nutrition. Paracentesis was performed 1 month post resection with removal of 2 L of fluid, notable for triglyceride level of 310 mg/dL (normal reference range <110 mg/dL). The ascites rapidly reaccumulated despite initiation and escalation of octreotide infusion (up to 8 mcg/kg/hr), medium chain triglyceride formula and, later, nil per os status. A second paracentesis was performed 2 weeks later with removal of 3.6 L of fluid. The patient was referred for lymphatic imaging and intervention.

Under general anesthesia, a paracentesis was performed with removal of 3 L of fluid. Conventional bilateral inguinal node lymphangiography was performed with ethiodized oil, revealing unilateral focus of retroperitoneal extravasation at L2 (Fig. 2). CBCT of the pelvis was performed, characterizing a left lateral external iliac chain lymph node with effluent drainage to the site of extravasation. The node was targeted percutaneously with a 25-gauge needle using CBCT with navigational overlay. After efferent drainage to the site of extravasation was again confirmed, embolization was performed into and across the extravasation using 0.5 mL of a 1:3 mixture of n-BCA to ethiodized oil. He remained on total parenteral nutrition for an additional week and subsequently was advanced to an unrestricted diet over 1 week without recurrence of ascites.

The patient went on to receive hematopoietic stem cell transplant. At the time of this report, he has undergone his fifth cycle of immunotherapy. Patient follow-up from time of intervention is currently 12 months.

**Discussion**

This description of 2 successful endolymphatic interventions for chyous ascites following neuroblastoma resection high-
lights a minimally invasive treatment option for this morbid condition. Each case demonstrated complete resolution of ascites for a mean follow-up of 26 months. No procedure-related complications were seen.

In both cases, a lymphatic leak was identified prior to targeted embolization. In larger case series, lymphatic leaks were identified in 55%-75% of patients [16,17]. Comparatively, prior reports on surgical intervention demonstrated identification in 80% of patients [18,19]. The use of ethiodized oil during lymphangiography has been shown to have a therapeutic effect, likely due to an inflammatory or embolic effect [17,20]. With this in mind, overall clinical success rates of these less invasive modalities can approach 90% [16,17].

Multiple previous reports demonstrate the feasibility and safety of embolizing lymph nodes or lymphatic networks with embolics such as n-BCA glue [14,21–25]. The n-BCA is mixed with ethiodized oil at various ratios to control the rate of polymerization and downstream propagation. Excessive down-
stream embolization must be avoided to prevent obstruction of normal central conducting channels such as cisterna chyli and thoracic duct. Targeting lymph nodes or channels in close proximity to the injury minimizes excessive embolization of upstream structures and theoretical risk of lymphedema. Additionally, administration of ethiodized oil should be limited to 0.25 mL/kg in children to avoid possible adverse outcomes such as pulmonary oil embolism [26,27].

Fig. 2 – Frontal fluoroscopic image following bilateral inguinal access and lymphangiography using ethiodized oil (A) demonstrated a single focus of lymphatic extravasation in the left retroperitoneum (arrow). Cone beam CT was performed (C), confirming the focus of extravasation (arrow) and further characterizing retroperitoneal lymphatic anatomy. A left lateral external iliac chain node was identified and targeted using cone beam CT guidance with navigational overlay (XperGuide, Philips) (C). Following contrast confirmation of inline drainage to the focus of extravasation, embolization was performed using cyanoacrylate (D) with preservation of the right-ided lymphatics.

Compared to thoracic duct embolization, embolization of retroperitoneal and mesenteric lymphatic injuries creates several technical challenges. Relative to the typical access channel in these interventions, the cisterna chyli, the involved ducts may be very small caliber, particularly in a pediatric patient. Accessing cisterna chyli with sufficiently caudal angulation for retrograde wire advancement introduced morbidity associated with transthoracic approaches. A technique of inferior thoracic duct embolization followed by retrograde reflux of sclerosant has been reported [28]. Percutaneous hepatic lymphatic access, transcervical thoracic duct arch access and endovascular entry through the venolym-
phatic junction may afford the retrograde access trajectory needed for infradiaphragmatic lymphatic interventions [29]. In this report, we described both direct access to the injury itself with refluxing embolization as well as upstream node access with downstream embolization with CBCT guidance to address the chylous ascites while minimizing nontarget lymphatic embolization, including preservation of the thoracic duct.

These cases exemplify the feasibility and efficacy of endolympathic interventions in iatrogenic pediatric chylous ascites. More studies are warranted to establish standardized techniques and long-term safety.

REFERENCES

[1] Evans JG, Spiess PE, Kamat AM, et al. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 2006;176(4 Pt 1):1463–7. doi:10.1016/j.juro.2006.06.016.

[2] Mosharafin AA, Foster RS, Koch MO, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 2004;171(5):1839–41. doi:10.1097/01.ju.0000120411.89737.90.

[3] Weniger M, D’Haese JC, Angele MK, Kleespies A, Werner J, Hartwig W. Treatment options for chylous ascites following major abdominal surgery: a systematic review. Am J Surg 2016;211(1):206–13. doi:10.1016/j.amjsurg.2015.04.012.

[4] Gaglioti PJ, Leevry CB, Koneru B. Peri-operative chylous ascites. J Med 1996;27(6):369–76.

[5] Camiel MR, Benninckhoff DL, Alexander LL. Chylous effusions, extravasation of lymphographic contrast material, hypoplasia of lymph nodes and lymphocytopenia. Chest 1971;59(1):107–10. doi:10.1378/chest.59.1.107.

[6] Taylor MD, Kim SS, Vaia JS. Therapeutic digoxin level in chylous drainage with no detectable plasma digoxin level. Chest 1998;114(5):1482–4. doi:10.1378/chest.114.5.1482.

[7] Strange C, Nicolau DP, Dryzer SR. Chylous transport of amiodarone. Chest 1992;101(2):573–4. doi:10.1378/chest.101.2.573.

[8] Repp R, Scheld HH, Bauer J, Becker H, Kreuder J, Netza H. Cyclosporine losses by a chylhotorax. J Heart Lung Trans 1992;11(2 Pt 1):397–8.

[9] Pio L, Boccardo F, Avanzi S, et al. Conservative management of chylous ascites after oncological surgery for peripheral neuroblastic tumors in pediatric patients. Lymphology 2019;52(1):25–34.

[10] Leibovitch I, Mor Y, Golomb J, Ramon J. The diagnosis and management of postoperative chylous ascites. J Urol 2002;167(2 Pt 1):449–57. doi:10.1097/01.ju.0000053922-20020200-00003.

[11] Karakol BS, Zenciroglu A, Gokce S, Kundak AA, Ipek MS. Therapeutic management of neonatal chylous ascites: report of a case and review of the literature. Acfa Paediatr Oslo Nor 2010;99(9):1307–10 1992. doi:10.1111/j.1651-2227.2010.01818.x.

[12] Chye JK, Lim CT, Van der Heuvel M. Neonatal chylous ascites-report of three cases and review of the literature. Pediatr Surg Int 1997;12(4):296–8. doi:10.1007/BF01372154.

[13] D’Agostino S, Costa L, Fabbro MA, Spina P, Musi L. [Neonatal chylous ascites: a case report and review of the literature]. Pediatr Medica E Chir Med Surg Pediatr 1998;20(4):285–6.

[14] Hill H, Srinivasa RN, Gemmets JJ, Hage A, Bundy J, Chick JFB. Endolympathic ethiodized oil intraonadal lymphangiography and cyanoacrylle glue embolization for the treatment of postoperative lymphatic leak after robot-assisted laparoscopic pelvic resection. J Endourol Case Rep 2018;4(1):66–71. doi:10.1089/cr.2018.0026.

[15] Srinivasa RN, Gemmets JJ, Osher ML, Hage AN, Chick JFB. Endolymphatic balloon-occluded retrograde abdominal lymphangiography (BORA) and embolization (BORAIE) for the diagnosis and treatment of chylous ascites: approach, technical success, and clinical outcomes. Ann Vasc Surg 2018;49:49–56. doi:10.1016/j.avsg.2017.10.020.

[16] Majdalany BS, Khayat M, Downing T, et al. Lymphatic interventions for isolated, iatrogenic chylous ascites: a multi-institution experience. Eur J Radiol 2018;109:41–7. doi:10.1016/j.ejrad.2018.10.019.

[17] Nadolski GJ, Chauhan NR, Itkin M. Lymphangiography and lymphatic embolization for the treatment of refractory chylous ascites. Cardiovasc Intervent Radiol 2018;41(3):415–23. doi:10.1007/s00270-017-1856-1.

[18] Lo TS, Chen FP, Chu KK, Soong YK. Successful management of chylous ascites after laparoscopic presacral neurectomy. J Am Assoc Gynecol Laparosc 1998;5(4):431–3. doi:10.1074/jal.1998.5.4.431.

[19] Laterre PF, Dugernier T, Reynaert MS. Chylous ascites: diagnosis, causes and treatment. Acta Gastro-Enterol Belg 2000;63(3):260–3.

[20] Matsumoto T, Yamagami T, Kato T, et al. The effectiveness of lymphangiography as a treatment method for various chyle leakages. Br J Radiol 2009;82(976):286–90. doi:10.1259/bjr/64849421.

[21] Itkin M, Nadolski GJ. Modern techniques of lymphangiography and interventions: current status and future development. Cardiovasc Intervent Radiol 2018;41(3):366–76. doi:10.1007/s00270-017-1863-2.

[22] Baek Y, Won JH, Chang S-J, et al. Lymphatic embolization for the treatment of pelvic lymphoceles: preliminary experience in five patients. JVsc Interv Radiol JVIR 2016;27(8):1170–6. doi:10.1016/j.jvir.2016.04.011.

[23] Hur S, Shin JH, Lee JI, et al. Early experience in the management of postoperative lymphatic leakage using lipiodol lymphangiography and adjunctive glue embolization. J Vasc Interv Radiol JVIR 2016;27(8):1177–1185 e1. doi:10.1016/j.jvir.2016.05.011.

[24] Chack JFB, Reddy SN, Nadolski GJ, Dori Y, Itkin M. Single-session endolymphatic glue embolization of lymphocele after heart transplantation. J Vasc Interv Radiol JVIR 2016;27(6):929–30. doi:10.1016/j.jvir.2016.02.023.

[25] Weaver MV, Tadros RO, Phangureh VS, Faries PL, Lookestein RA, Marin ML. A novel approach to the management of a recurrent lymphocele following a femoral-femoral bypass. J Vasc Surg 2014;59(4):1109–11. doi:10.1016/j.jvs.2013.04.049.

[26] Gouch MH. Lymphangiography in Children. Arch Dis Child 1964;39(204):177–81.

[27] Rajebi MR, Chaudry G, Padua HM, et al. Intranodal lymphangiography: feasibility and preliminary experience in children. J Vasc Interv Radiol JVIR 2011;22(9):1300–5. doi:10.1016/j.jvir.2011.05.003.
[28] Srinivasa RN, Chick JF, Gemmete JJ, Hage AN, Srinivasa RN. Endolymphatic interventions for the treatment of chylothorax and chylous ascites in neonates: technical and clinical success and complications. Ann Vasc Surg 2018;50:269–74.

[29] Bundy JJ, Chick JF, Jiao A, Cline MR, Srinivasa RN, Khayat M, et al. Percutaneous fluoroscopically-guided transcervical retrograde access facilitates successful thoracic duct embolization after failed antegrade transabdominal access. Lymphology 2019;52(2):52–60.